CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
The CCTG CO28 correlative study: Tumour-free ctDNA detection as a decision tool to support organ preservation in node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision, and observation, was presented by Dr Jonathan Loree at GI ASCO 2025. This oral abstract assessed circulating tumor DNA (ctDNA) in patients with T1-T3, N0 rectal cancer and found that ctDNA effectively identifies cancers with inadequate response to chemotherapy for which a more radical surgery is recommended.
The recently opened ALC8 treatment trial will be testing the effects of novel therapeutics for newly diagnosed, untreated patients with acute myeloid leukemia (AML). Researchers want to compare the usual treatment for high-risk AML with four different combinations of treatment.
Change often comes with both excitement and the inevitable goodbye.
La Dre Rahima Jamal et Camille Amiel préparent le patient à prendre les capsules de microbiote fécal. Photo : Centre hospitalier de l’Université de Montréal (CHUM)
